Trobalt

RSS
Withdrawn

This medicine's authorisation has been withdrawn

retigabine
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 19 July 2018, the European Commission withdrew the marketing authorisation for Trobalt (retigabine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Glaxo Group Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Trobalt was granted marketing authorisation in the EU on 28 March 2011 for adjunctive treatment of partial onset seizures. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2016. 

The European Public Assessment Report (EPAR) for Trobalt is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (602.21 KB - PDF)

View

español (ES) (570.89 KB - PDF)

View

čeština (CS) (588.03 KB - PDF)

View

dansk (DA) (571.77 KB - PDF)

View

Deutsch (DE) (566.87 KB - PDF)

View

eesti keel (ET) (568.93 KB - PDF)

View

ελληνικά (EL) (663.17 KB - PDF)

View

français (FR) (571.85 KB - PDF)

View

hrvatski (HR) (563.56 KB - PDF)

View

italiano (IT) (576.81 KB - PDF)

View

latviešu valoda (LV) (596.81 KB - PDF)

View

lietuvių kalba (LT) (571.43 KB - PDF)

View

magyar (HU) (586.13 KB - PDF)

View

Malti (MT) (579.27 KB - PDF)

View

Nederlands (NL) (570.47 KB - PDF)

View

polski (PL) (587.24 KB - PDF)

View

português (PT) (572.32 KB - PDF)

View

română (RO) (570.88 KB - PDF)

View

slovenčina (SK) (600.73 KB - PDF)

View

slovenščina (SL) (593.62 KB - PDF)

View

Suomi (FI) (568.59 KB - PDF)

View

svenska (SV) (569.68 KB - PDF)

View

Product information

български (BG) (1.4 MB - PDF)

View

español (ES) (892.69 KB - PDF)

View

čeština (CS) (1.39 MB - PDF)

View

dansk (DA) (1020.94 KB - PDF)

View

Deutsch (DE) (1.38 MB - PDF)

View

eesti keel (ET) (1 MB - PDF)

View

ελληνικά (EL) (1.55 MB - PDF)

View

français (FR) (916.28 KB - PDF)

View

hrvatski (HR) (1.11 MB - PDF)

View

íslenska (IS) (1.14 MB - PDF)

View

italiano (IT) (1.01 MB - PDF)

View

latviešu valoda (LV) (1.29 MB - PDF)

View

lietuvių kalba (LT) (1.23 MB - PDF)

View

magyar (HU) (1.36 MB - PDF)

View

Malti (MT) (1.45 MB - PDF)

View

Nederlands (NL) (1.05 MB - PDF)

View

norsk (NO) (991.35 KB - PDF)

View

polski (PL) (1.47 MB - PDF)

View

português (PT) (1.03 MB - PDF)

View

română (RO) (1.35 MB - PDF)

View

slovenčina (SK) (1.34 MB - PDF)

View

slovenščina (SL) (1.29 MB - PDF)

View

Suomi (FI) (981.88 KB - PDF)

View

svenska (SV) (1.02 MB - PDF)

View
Latest procedure affecting product information: IAIN/0043
19/07/2018
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (497.89 KB - PDF)

View

español (ES) (484.24 KB - PDF)

View

čeština (CS) (491.97 KB - PDF)

View

dansk (DA) (478.19 KB - PDF)

View

Deutsch (DE) (478.46 KB - PDF)

View

eesti keel (ET) (477.69 KB - PDF)

View

ελληνικά (EL) (496.42 KB - PDF)

View

français (FR) (478.17 KB - PDF)

View

hrvatski (HR) (477.95 KB - PDF)

View

íslenska (IS) (478.89 KB - PDF)

View

italiano (IT) (478.36 KB - PDF)

View

latviešu valoda (LV) (489.94 KB - PDF)

View

lietuvių kalba (LT) (479.38 KB - PDF)

View

magyar (HU) (488.87 KB - PDF)

View

Malti (MT) (490.51 KB - PDF)

View

Nederlands (NL) (476.61 KB - PDF)

View

norsk (NO) (478.89 KB - PDF)

View

polski (PL) (489.77 KB - PDF)

View

português (PT) (477.16 KB - PDF)

View

română (RO) (477.35 KB - PDF)

View

slovenčina (SK) (490.23 KB - PDF)

View

slovenščina (SL) (489.58 KB - PDF)

View

Suomi (FI) (476.51 KB - PDF)

View

svenska (SV) (464.35 KB - PDF)

View

Product details

Name of medicine
Trobalt
Active substance
retigabine
International non-proprietary name (INN) or common name
retigabine
Therapeutic area (MeSH)
Epilepsy
Anatomical therapeutic chemical (ATC) code
N03AX21

Pharmacotherapeutic group

Antiepileptics

Therapeutic indication

Trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.

Authorisation details

EMA product number
EMEA/H/C/001245
Marketing authorisation holder
Glaxo Group Limited 

Glaxo Group Limited
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom

Marketing authorisation issued
27/03/2011
Withdrawal of marketing authorisation
19/07/2018
Revision
12

Assessment history

This page was last updated on

Share this page